155 NDCs across 33 manufacturers|144 Generic,11 Brand
Levetiracetam, originally Keppra, is a broad-spectrum anticonvulsant used across partial-onset, myoclonic, and generalized tonic-clonic seizures. Generic tablets and oral solution are cheap and heavily competed, while the 3D-printed dissolving tablet Spritam and extended-release forms occupy the upper price tiers. Its clean drug-interaction profile has made it one of the most-prescribed anti-seizure medicines.
▸ More about this market▾ Less
Levetiracetam is used to treat partial epilepsies, tonic-clonic epilepsy and juvenile myoclonic epilepsy, per the National Library of Medicine's MED-RT classification. The brand product was first FDA-approved on Nov 30, 1999, and the first generic was approved Nov 4, 2008. FDA's Orange Book lists 94 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $255 million on Levetiracetam across 4.9 million claims for 849,000 beneficiaries.
Levetiracetam is available as 155 NDCs from 33 manufacturers (144 generic, 11 brand), with NADAC prices from $0.05 to $19.87 per EA — the most expensive product costs about 402× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
155
144G / 11B
Manufacturers
33
competing in market
Price Spread
$0.05 – $19.87
per EA, 143 of 155 NDCs
7d Activity
107↑13↓35 flat
avg +2.1% WoW · of 155 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Levetiracetam is used to treat partial epilepsies, tonic-clonic epilepsy and juvenile myoclonic epilepsy, per the National Library of Medicine's MED-RT classification.
When did Levetiracetam become available as a generic?
FDA approved the first generic Levetiracetam (ANDA) on Nov 4, 2008. The Orange Book currently lists 94 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Levetiracetam?
In 2024, Medicare Part D spent $255 million on Levetiracetam across 4.9 million claims for 849,000 beneficiaries.
How many Levetiracetam products are on the market?
The Levetiracetam drug market contains 155 NDCs from 33 manufacturers — 144 generic and 11 brand products.
What is the price range for Levetiracetam?
NADAC reference prices for Levetiracetam range from $0.0494 to $19.8744 per EA — the most expensive product costs about 402× the cheapest. 12 additional products are priced per different units (e.g. liquids per ML) and aren't directly comparable.
Is generic Levetiracetam cheaper than brand?
The average generic NADAC for Levetiracetam is $0.1178 per EA, versus $11.4895 for brand-labeled products — brand versions average about 98× the generic price.
Which manufacturers make Levetiracetam?
33 manufacturers list Levetiracetam in NADAC. Ranked by number of NDCs, the largest are Torrent Pharmaceuticals Limited (18), Lupin Pharmaceuticals Inc. (12), BluePoint Laboratories (9), Solco Healthcare US LLC (8), Rising Pharma Holdings Inc. (8).
How has the price of Levetiracetam changed recently?
Over the past 7 days, 107 Levetiracetam NDCs rose and 13 fell, with a market-wide average change of +2.1%.